Skip to main content

Table 4 Treatment discontinuation on first-line therapy with aromatase inhibitors before vs. after 5 months - from chart review

From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

Variable Level Treatment discontinuation ≤ 5 months (N = 26) Treatment discontinuation > 5 months (N = 76) p-value
Stage at diagnosis Early (Stage IA, IB, IIA, IIB) 5 19.2% 12 15.8% 0.4740b
Limited Regional (Stage IIIA) 2 7.7% 1 1.3%
Locally Advanced (Stage IIIB) 0 0.0% 1 1.3%
Locally Advanced (Stage IIIC) 0 0.0% 2 2.6%
Metastatic (Stage IV) 19 73.1% 60 78.9%
ECOG performance status at the time of diagnosis of mBC a 0 9 34.6% 28 36.8% 0.8021
1 13 50.0% 40 52.6%
2 4 15.4% 8 10.5%
3 0 0.0% 0 0.0%
De novo / relapse De novo 19 73.1% 61 80.3% 0.5575b
Relapse from adjuvant 7 26.9% 14 18.4%
Don’t know 0 0.0% 1 1.3%
Adjuvant treatment received Yes 8 30.8% 17 22.4% 0.4328b
No 18 69.2% 59 77.6%
Don’t know 0 0.0% 0 0.0%
Aromatase inhibitors received in first-line Anastrozole 16 61.5% 46 60.5% 0.0036b
Exemestane 5 19.2% 1 1.3%
Letrozole 5 19.2% 29 38.2%
Visceral disease Yes 15 57.7% 31 40.8% 0.1349
No 11 42.3% 45 59.2%
  1. mBC metastatic breast cancer
  2. One patient using aromatase inhibitors in first-line was excluded due to treatment discontinuation (patient choice) at 3 months
  3. aDefinition of ECOG performance statuses; 0: Fully active, able to carry on all pre-disease performance without restriction; 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work; 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3: Capable of only limited self-care, confined to bed or chair more than 50% of walking hours
  4. bExact Fisher test